Tilray Gains 38% Following DEA Approval - Adviser Investments

Tilray Gains 38% Following DEA Approval

Rick Winters, vice president at Adviser Investments, has the market analysis for Wednesday, September 19. Major U.S. stock indexes saw mixed results, with the Dow Jones Industrial Average and S&P 500 gaining 0.6% and 0.1%, respectively, and the NASDAQ experiencing fractional losses. Microsoft declined 1.3% on tariff-related concerns—despite announcing a 10% dividend increase. Canadian medical marijuana producer Tilray saw dramatic price fluctuations: Its stock peaked up 98% intraday before closing with 38% gains after the Drug Enforcement Administration announced its approval of the company’s plan to import and test cannabis within the United States.

Recent Videos

View All Videos

Lowell on China’s Evergrande Debacle

Wiener on the ETF Edge Podcast

Wiener Talks China on CNBC

Lowell on Fox Business: Market Still Has Room to Run

Adviser Investments' logo is a registered trademark of Adviser Investments, LLC.